GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 206 filers reported holding GENMAB A/S in Q2 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $437,066 | -82.2% | 12,392 | -80.8% | 0.00% | -80.0% |
Q2 2023 | $2,450,277 | +0.7% | 64,464 | +0.0% | 0.01% | +66.7% |
Q1 2023 | $2,433,103 | -14.6% | 64,436 | -4.1% | 0.01% | -66.7% |
Q4 2022 | $2,848,530 | +34.0% | 67,214 | +1.6% | 0.02% | -30.8% |
Q3 2022 | $2,125,000 | +7.3% | 66,142 | +8.5% | 0.03% | +18.2% |
Q2 2022 | $1,980,000 | -1.8% | 60,960 | +9.4% | 0.02% | -29.0% |
Q1 2022 | $2,017,000 | -24.0% | 55,730 | -16.9% | 0.03% | -22.5% |
Q4 2021 | $2,654,000 | +2.1% | 67,049 | +12.7% | 0.04% | -29.8% |
Q3 2021 | $2,600,000 | +6.7% | 59,504 | -0.3% | 0.06% | +7.5% |
Q2 2021 | $2,436,000 | +24.5% | 59,671 | +0.1% | 0.05% | +15.2% |
Q1 2021 | $1,957,000 | -22.7% | 59,605 | -4.3% | 0.05% | -43.2% |
Q4 2020 | $2,533,000 | +26.1% | 62,296 | +13.6% | 0.08% | -2.4% |
Q3 2020 | $2,008,000 | +703.2% | 54,857 | +344.5% | 0.08% | +453.3% |
Q3 2019 | $250,000 | – | 12,340 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |